Friday, April 5, 2013

Hepatitis C Viral Load Fluctuates Without Treatment

 
Hepatitis C Viral Load Fluctuates Without Treatment
 
Megan Brooks
Apr 04, 2013
Fluctuations in circulating hepatitis C virus RNA could be "clinically meaningful" in a substantial number of patients with chronic infection, and could influence the best time to prescribe antiviral therapy.

"Decisions based on early viral kinetics, such as early stopping rules, may require the testing of baseline specimens collected closest to treatment initiation," said researcher Vincent Soriano, MD, from Hospital Carlos III in Madrid, Spain.

He presented study results at the International Conference on Viral Hepatitis 2013 in New York City, which was sponsored by the International Association of Providers of AIDS Care and the Icahn School of Medicine at Mount Sinai.

Dr. Soriano and his team conducted a retrospective review of longitudinal plasma hepatitis C RNA determinations in 818 consecutive untreated patients with chronic virus seen at a clinic in Madrid. For comparison, the researchers used longitudinal plasma human immunodeficiency virus (HIV) RNA measurements from 333 untreated HIV patients followed at the same clinic.

They analyzed 3169 hepatitis C RNA values obtained over 66.2 months and 1998 HIV RNA values obtained over 27.3 months.

Overall, a variation in viral RNA greater than 0.5-log IU/mL occurred more often in hepatitis C specimens than in HIV specimens (44% vs 23%; P < .001). The same was true for variations greater than 1.0-log IU/mL (15% vs 4%; P < .001).

On multivariate analysis, predictors of viral variations greater than 0.5-log IU/mL were lower hepatitis C RNA levels (odds ratio [OR], 0.35; 95% confidence interval [CI], 0.26 - 0.47; P = .001), HIV coinfection (OR, 2.57; 95% CI, 1.56 - 2.68; P < .001), and IL28B-CC alleles (OR, 1.87; 95% CI, 1.28 - 2.74; P = .001).

This study "confirms something that many people knew, that fluctuations in hepatitis C RNA levels are greater and more variable than those of HIV," conference cochair Douglas Dieterich, MD, from the Icahn School of Medicine at Mount Sinai, told Medscape Medical News.

"Using response-guided therapy [RGT] with the new direct-acting antivirals has become the standard of care, and the baseline level of hepatitis C RNA is a very important component of RGT," Dr. Dieterich added. "The timing of treatment to maximize hepatitis C RNA may be a new way to increase treatment success."

Dr. Soriano reports relationships with Boehringer Ingelheim Pharmaceuticals, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and AbbVie. Dr. Dieterich reports relationships with Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Genentech, and Novartis Pharmaceuticals.

International Conference on Viral Hepatitis (ICVH) 2013: Oral Abstract 10. Presented March 25, 2013.

http://www.medscape.com/viewarticle/781957

Thursday, April 4, 2013

Oklahoma Dental Association Issues Statement on Infection Control in Dental Settings

Recently, a Tulsa, Okla. area dentist was cited with putting patients at risk of infection with hepatitis by failing to follow proper infection control practices. The Oklahoma Dental Association is closely monitoring the situation.

“Infection control procedures are there for one reason, to protect the patients,” says Dr. C. Todd Bridges, president of the Oklahoma Dental Association. “This alleged breach may have placed patients at risk, and it is clearly an aberration that in no way reflects the way dentists typically operate. The reason this situation is so alarming is because it is so rare.”

The Oklahoma Dental Association recommends that all practicing dentists, dental team members and laboratories follow standard precautions specified by the Centers for Disease Control and Prevention (CDC). Examples of infection control in the dental office include the use of masks, gloves, surface disinfectants and sterilizing reusable dental devices.

“We recommend that people talk with their dentists about infection control,” says Bridges. “Dentists are universally proud of the cleanliness of their offices and will not be offended when patients ask questions about infection control protocols.”

The CDC's guidelines for infection control

Source: Oklahoma Dental Association

Role for Radiation in Locally Advanced Liver Cancer


Medscape Medical News > Oncology

Role for Radiation in Locally Advanced Liver Cancer

Radiation could play a role in the treatment of locally advanced hepatocellular carcinoma (HCC), according a prospective series of 102 patients treated with patient-specific stereotactic body radiation therapy (SBRT).

Results of the study were published online April 1 in the Journal of Clinical Oncology.

All patients had Child-Turcotte-Pugh class A disease and were unsuitable for standard locoregional therapies, report Alexis Bujold, MD, and colleagues from the University Health Network, University of Toronto, in Ontario, Canada. Most had underlying liver disease (38% hepatitis B, 38% hepatitis C, 25% alcohol-related). Patients in 2 trials received individualized SBRT (dose range, 24 to 54 Gy) in 6 fractions; results were then pooled.

The results show a 1-year survival rate of 55% and a median survival of 17 months after SBRT.

This compares favorably with results seen with the only other potential therapies available for this patient population, the researchers note. For best supportive care, the 1-year survival rate was 18% to 33% (median, 4.2 - 7.9 months); for sorafenib, the rate was 29% to 44% (median, 6.5 - 10.7 months).

These results add "to the growing body of evidence that liver tumors can be treated with durable local control with radiation," writes Theodore Hong, MD, from the Massachusetts General Hospital in Boston, in an accompanying editorial.

"However, the question of where radiation fits into the armamentarium of therapies for HCC remains," he continues.

Where Does Radiation Fit In?

Clearly, surgery remains the gold standard for localized disease, but only a small minority of patients with liver-confined HCC meets the tumor-specific and medical criteria for an operation, Dr. Hong points out.

For the remaining patients, therapeutic options include radiofrequency ablation and transarterial chemoembolization, but the efficacy of both of these is limited in larger tumors, he notes.

Another option is sorafenib, which has shown significant disease control in unresectable HCC, but the clinical activity is modest and the drug is associated with significant adverse effects, he explains.

Radiation is a potentially ablative liver-directed therapy that is complementary to existing options, and Dr. Hong suggests that the greatest benefits could be seen in high-risk patients. Significantly, this includes patients with tumor vascular thrombus, which is readily treatable with radiation therapy, he adds. Dr. Bujold and colleagues demonstrate that radiation therapy can be used to recanalize tumor-thrombosed vasculature.

However, randomized trials are needed to see if the "impressive local control" currently seen with radiation translates to a clinically meaningful survival benefit in patients with high-risk HCC, he cautions. Many previous series that have evaluated radiation therapy for HCC show results similar to those found by Dr. Bujold and colleagues: excellent local control but a precipitous drop in survival at 2 to 3 years.

New Trial Planned

Both the editorialist and the researchers discuss a planned trial that will address some of these issues. The Radiation Therapy Oncology Group (RTOG) is planning a randomized study comparing sorafenib alone with sorafenib plus SBRT in patients with HCC and vascular involvement.
"In addition to answering the question of whether radiation improves outcome in high-risk patients with HCC, this study will provide a significant education opportunity to the oncology community," writes Dr. Hong, because it includes imaging and contouring consensus guidelines in the protocol.
"Whether radiation is ready to be a new standard of care in high-risk patients with HCC will depend on meaningful support of this critical randomized trial," he concludes.

Dr. Bujold has disclosed no relevant financial relationships. Coauthor Laura Dawson, MD, reports receiving research funding from Bayer. Coauthor Morris Sherman, PhD, reports receiving remuneration from Arqule. Dr. Hong reports serving in a consultancy or advisory role for Illumina.
J Clin Oncol.

Published online April 1, 2013. Abstract, Editorial



Davidson County couple Donates Life

DAVIDSON COUNTY, N.C.–Like most young couples, Casey and Shelley Shepherd love to think about their future, but up until last January, that felt impossible.

Source

Management of patients with complications of cirrhosis

Management of patients with complications of cirrhosis

Christopher Fowler PhD, MBA, RN, ACNP-BC

The Nurse Practitioner: The American Journal of Primary Health Care

April 2013 Volume 38 Number 4 Pages 14 - 22

Despite significant improvements in medical care, the management of patients with cirrhosis remains challenging with less than optimal results. Although liver transplantation is the most effective treatment for end-stage liver disease and survival after transplant has consistently improved over the years, a scarcity of donor organs and growing incidence of cirrhosis requires continued improvement in ways to manage this complex group of patients.
 
Clinicians caring for individuals with chronic liver disease must remain vigilant for subtle changes in patient condition. Patients and caregivers must be educated to encourage frequent follow-up, adherence to prescribed therapeutic regimens, and communication regarding adverse reactions
 
Full article can be found @ Nursing Center.com

Monogamous heterosexuals unlikely to transmit Hepatitis C

Monogamous heterosexuals unlikely to transmit Hepatitis C

Individuals infected by the hepatitis C virus (HCV) have nothing to fear from sex in a monogamous, heterosexual relationship. Transmission of HCV from an infected partner during sex is rare according to new research published in Hepatology, a journal published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD).

Experts estimate that HCV affects up to 4 million Americans, most of whom are sexually active. Medical evidence shows HCV is primarily transmitted by exposure to infectious blood, typically through intravenous (IV) drug use. However, there are conflicting reports regarding sexual activity and HCV transmission with some studies suggesting that exposure to infected blood during sex—through bodily fluids such as vaginal secretions, semen or saliva—may carry a minimal infection risk.

“Generally the risk for transmitting HCV to sex partners is very low,” explains lead study author Dr. Norah Terrault with the University of California, San Francisco. “Yet, lack of quantitative data about the risk of HCV transmission with sexual activity remains a limitation for doctors counseling their patients on safe sex practices.”

To specifically quantify the risk HCV transmission from a chronically infected individual to their sex partner, researchers recruited 500 anti-HCV-positive individuals, who were negative for the human immunodeficiency (HIV), and their long-term heterosexual partners. Couples were surveyed about lifetime risk factors for HCV infection, sexual practices of the couple, and sharing of personal items. The team analyzed blood samples to determine the presence or absence of active virus in the blood and compared the HCV strains in those couples with HCV present.

The majority of HCV infected individuals who participated in the study were non-Hispanic whites, had a median age of 49 years, and sexual activity with their partners ranging from 2 to 52 years. HCV prevalence among partners was 4%, with 9 couples having similar viral strains and viral samples from 3 couples were highly related which is consistent with HCV transmission between the partners.

The maximum incidence rate of HCV transmission by sex was 0.07% per year or roughly 1 per 190,000 sexual contacts that researchers based upon 8377 person-years of follow-up. The team did not identify any specific sexual practices linked to HCV infections among the couples. “Our study provides clinicians with important information for counseling chronic HCV patients in long-term sexual relationships, supporting the current recommendations that couples not change their sexual practices if they are in a monogamous heterosexual relationship,” concludes Dr. Terrault.

(Source: Wiley: Hepatology)
Photo Source: Dan Heller

Wednesday, April 3, 2013

Medicare patients need hepatitis C tests, coalition says

Medicare patients need hepatitis C tests, coalition says

By Elise Viebeck - 04/03/13 10:52 AM ET

Medicare should promote screenings for hepatitis C given the frequency of the virus among older patients, advocates said Wednesday.

The National Viral Hepatitis Roundtable, a coalition of health groups and medical providers, circulated a letter urging federal health officials to offer hepatitis C screenings as part of patients' first Medicare exam.
The advocates said baby boomers represent 75 percent of U.S. cases of hepatitis C and that screening them for the virus could save more than 100,000 lives.

Read More...

Mon, Apr 01, 2013 - 08:13

Formal HCV education improved time to therapy initiation, response

Formal HCV education improved time to therapy initiation, response
  • April 3, 2013
Patients with hepatitis C who participated in a formal class on the illness initiated therapy more quickly and experienced sustained virologic response more frequently than those who did not attend in a recent study.

Researchers conducted a cross-sectional survey of 94 primary care providers in San Francisco and performed a retrospective records review of 118 patients with HCV before and after development of a formal HCV education class. The 2-hour class was presented by a liver clinic nurse practitioner and included topics on the symptoms, diagnosis and transmission of HCV, along with candidacy for, response to and side effects of therapy.

Full Story »